• Assay Type

  Solid Phase Sandwich ELISA

• Format

  96-well strip plate

• Sample Type & Volume Required

  100 µL

• Range

  31.20 - 2,000 pg/mL

• Sufficient Materials

  For five 96-well plates*

• Specificity

  Please see the

* Provided that the recommended microplates, buffers, diluents, substrates and solutions are used, and the assay is run as summarized in the Assay Procedure provided.

Ancillary Reagent Kit Available  

DY008, DuoSet ELISA Ancillary Reagent Kit 2 -

This DuoSet ELISA Development kit contains the basic components required for the development of sandwich ELISAs to measure natural and Recombinant

Product Features

• Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time

• Development protocols are provided to guide further assay optimization

• Assay can be customized to your specific needs

• Economical alternative to complete kits

Kit Content

• Capture Antibody

• Detection Antibody

• Recombinant Standard

• Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)

Other Reagents Required

  PBS: (Catalog # ), or 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na  ₂HPO  ₄, 1.5 mM KH  ₂PO  ₄, pH 7.2 - 7.4, 0.2 µm filtered  
 
  Wash Buffer: (Catalog # ), or equivalent  
 
  Reagent Diluent*  
 
  Blocking Buffer*  
 
  Substrate Solution: 1:1 mixture of Color Reagent A (H  ₂O  ₂) and Color Reagent B (Tetramethylbenzidine) (Catalog # )  
 
  Stop Solution: 2 N H  ₂SO  ₄ (Catalog # )  
 
  Microplates: R&D Systems (Catalog # ), or equivalent  
 
  Plate Sealers: ELISA Plate Sealers (Catalog # ), or equivalent  
 

*For the Reagent Diluent and Blocking Buffer recommended for a specific DuoSet ELISA Development Kit, please see the product

Preparation and Storage

• Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: SOST/Sclerostin

SOST, also known as Sclerostin, is a Cerberus/DAN family BMP antagonist and is an important regulator of bone homeostasis. Inactivating mutations in the SOST gene can cause sclerosteosis and van Buchem disease. SOST is expressed by terminally differentiated cells embedded in mineralized matrix including osteocytes, hypertrophic and prehypertrophic chondrocytes, and tooth cementocytes. Its expression is induced by BMP-2, -4, and -6 and is inhibited by parathyroid hormone (PTH). Its downregulation in osteocytes by physical loading of bone contributes to the mechanical sensor function of osteocytes and the subsequent increase in bone growth. SOST binds to BMP-2, -4, -5, -6, and -7 and inhibits the osteogenic differentiation induced by these BMPs. It inhibits canonical Wnt signaling by binding to LRP-5 and LRP-6 and inhibiting their association with Frizzled receptors. SOST reduces the proliferation of mesenchymal stem cells (MSC) and induces MSC apoptosis. Circulating levels of SOST are elevated in pathologies with bone involvement including low bone mineral density, Paget’s disease, multiple myeloma, and prostate cancer with bone metastases. It is also elevated in advanced chronic kidney disease, alcoholic liver disease, type 2 diabetes, and patients with increased abdominal and gynoid fat.

• Entrez Gene IDs:

  50964 (Human); 74499 (Mouse);

• Aliases:

  sclerostin; SOST; VBCHsclerosteosis